Clinical significance of interleukin 33 (il-33) in patients with eosinophilic pneumonia

Allergology International

Volumn 62, Issue 1, 2013, Pages 45-52

  Mato, Naoko ^a   Bando, Masashi ^a   Kusano, Aya ^a   Hirano, Toshikatsu ^a   Nakayama, Masayuki ^a   Uto, Tomohiro ^b   Nakaya, Takakiyo ^a   Yamasawa, Hideaki ^a   Sugiyama, Yukihiko ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Eosinophil; Eosinophilic pneumonia; IL 33; IL 5; Th2 cytokine

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5;

ACUTE DISEASE; ADULT; ARTICLE; CHRONIC DISEASE; CONCENTRATION (PARAMETERS); CORRELATIONAL STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LOEFFLER PNEUMONIA; LUNG LAVAGE; MALE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; TH2 CELL;

EID: 84875157216     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.12-OA-0439     Document Type: Article

References (36)

1. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90.
2. Tominaga S, Jenkins NA, Gilbert DJ, Copeland NG, Tetsuka T. Molecular cloning of the murine ST2 gene. Characterization and chromosomal mapping. Biochim Biophys Acta 1991;1090:1-8.
3. Sweet MJ, Leung BP, Kang D et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001;166:6633-9.
4. Mato N, Fujii M, Hakamata Y et al. Interleukin-1 receptorrelated protein ST2 suppresses the initial stage of bleomycin-induced lung injury. Eur Respir J 2009;33: 1415-28.
5. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008;121:1484-90.
6. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009;113:1526-34.
7. Kondo Y, Yoshimoto T, Yasuda K et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008;20:791-800.
8. Oboki K, Ohno T, Kajiwara N et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010;107:18581-6.
9. Préfontaine D, Lajoie-Kadoch S, Foley S et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009;183: 5094-103.
10. Sakashita M, Yoshimoto T, Hirota T et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy 2008;38:1875-81.
11. Mato N, Bando M, Yamasawa H et al. [Role of IL-33 in bronchial asthma]. Nihon Kokyuki Gakkai Zasshi 2010;48: 419-25 (in Japanese).
12. Travis WD, Colby TV, Koss MN et al. Non-Neoplastic Disorders of the Lower Respiratory Tract. Washington, DC: The American Registry of Pathology, Armed Forces Institute of Pathology, 2001;160-7.
13. Allen JN, Pacht ER, Gadek JE, Davis WB. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 1989;321:569-74.
14. Carrington CB, Addington WW, Goff AM et al. Chronic eosinophilic pneumonia. N Engl J Med 1969;280:787-98.
15. Hayakawa H, Sato A, Toyoshima M, Imokawa S, Taniguchi M. A clinical study of idiopathic eosinophilic pneumonia. Chest 1994;105:1462-6.
16. Mochimaru H, Kawamoto M, Fukuda Y, Kudo S. Clinicopathological differences between acute and chronic eosinophilic pneumonia. Respirology 2005;10:76-85.
17. Miyazaki E, Nureki S, Ono E et al. Circulating thymusand activation-regulated chemokine/CCL17 is a useful biomarker for discriminating acute eosinophilic pneumonia from other causes of acute lung injury. Chest 2007; 131:1726-34.
18. Nakahara Y, Hayashi S, Fukuno Y, Kawashima M, Yatsunami J. Increased interleukin-5 levels in bronchoalveolar lavage fluid is a major factor for eosinophil accumulation in acute eosinophilic pneumonia. Respiration 2001;68: 389-95.
19. Allen JN, Liao Z, Wewers MD, Altenberger EA, Moore SA, Allen ED. Detection of IL-5 and IL-1 receptor antagonist in bronchoalveolar lavage fluid in acute eosinophilic pneumonia. J Allergy Clin Immunol 1996;97:1366-74.
20. Philit F, Etienne-Mastroïanni B, Parrot A, Guérin C, Robert D, Cordier JF. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002;166:1235-9.
21. Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia. A report of 19 cases and review of the literature. Medicine (Baltimore) 1988;67:154-62.
22. Bernard GR, Artigas A, Bringham KL et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149: 818-24.
23. Rennard SI, Basset G, Lecossier D et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60:532-8.
24. Préfontaine D, Nadigel J, Chouiali F et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010;125:752-4.
25. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 2008;3:e3331.
26. Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity 2009;31:5-7.
27. Julie AW, Murray CH, Adriano GR et al. Cigarette smoke prevents apoptosis through inhibition of caspase activation and induces necrosis. Am J Respir Cell Mol Biol 2003; 29:562-70.
28. Kode A, Yang SR, Rahman I. Differential effects of cigarette smoke on oxidative stress and proinflammatory cytokine release in primary human airway epithelial cell and in a variety of transformed alveolar epithelial cells. Respir Res 2006;7:132.
29. Albertine KH, Soulier MF, Wang Z et al. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol 2002; 161:1783-96.
30. Matute-Bello G, Liles WC, Radella F 2nd et al. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;156:1969-77.
31. Kurowska-Stolarska M, Kewin P, Murphy G et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergicinduced airway inflammation independent of IL-4. J Immunol 2008;181:4780-90.
32. Allakhverdi Z, Comeau MR, Smith DE et al. CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol 2009;123:472-8.
33. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol 2010;185:3472-80.
34. Denburg JA, Keith PK. Eosinophils progenitors in airway disease: clinical implications. Chest 2008;134:1037-43.
35. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type response. J Immunol 2011;186:4375-87.
36. Lefrançais E, Roga S, Gautier V et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 2012;109:1673-8.